![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2009 RNA Society Knockdown of SLBP results in nuclear retention of histone mRNA 1Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA 2Program in Molecular Biology and Biotechnology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA 3These authors contributed equally to this work.
Reprint requests to: Eric J. Wagner, Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, 7000 Fannin, Houston, Texas 77030, USA; e-mail: Eric.J.Wagner/at/uth.tmc.edu. Received June 5, 2008; Accepted November 14, 2008. Abstract Histone mRNAs are the only eukaryotic cellular mRNAs that are not polyadenylated. Synthesis of mature histone mRNA requires only a single processing reaction: an endonucleolytic cleavage between a conserved stem–loop and a purine-rich downstream element to form the 3′ end. The stem–loop binding protein (SLBP) is required for processing, and following processing, histone mRNA is transported to the cytoplasm, where SLBP participates in translation of the histone mRNA and is also involved in regulation of histone mRNA degradation. Here we present an analysis of histone mRNA metabolism in cells with highly reduced levels of SLBP using RNA interference. Knocking down SLBP in U2OS cells results in a reduction in the rate of cell growth and an accumulation of cells in S-phase. Surprisingly, there is only a modest (twofold) decrease in histone mRNA levels. Much of histone mRNA in the SLBP knockdown cells is properly processed but is retained in the nucleus. The processed histone mRNA in SLBP knockdown cells is not rapidly degraded when DNA replication is inhibited. These results suggest a previously undescribed role for SLBP in histone mRNA export. Keywords: 3′-end formation, stem–loop binding protein, histone mRNA, mRNA export INTRODUCTION The replication-dependent histone mRNAs are the only eukaryotic cellular mRNAs that are not polyadenylated, ending instead in a conserved stem–loop (SL) (Marzluff 2005). These mRNAs lack introns and undergo a single processing reaction cleaving the nascent pre-mRNA from the DNA template and producing the mature mRNA. The cleavage reaction requires the stem–loop 5′ of the cleavage site and a purine-rich region, the histone downstream element (HDE), located ~10 nucleotides (nt) 3′ of the cleavage site. The HDE base pairs with the U7 small nuclear RNA, which is a component of the U7 snRNP (Mowry and Steitz 1987). The stem–loop binding protein (SLBP) binds to the SL and helps stabilize the interaction of U7 snRNP with the pre-mRNA. Several lines of evidence support this model. Pull-down of biotinylated histone pre-mRNA from nuclear extracts results in the concomitant pull-down of the U7 snRNA (Dominski et al. 1999, 2001), which is enhanced by SLBP. In vitro processing of histone pre-mRNA is absolutely dependent on SLBP if the HDE does not interact strongly with U7 snRNA (Dominski et al. 1999). The factor ZFP100 interacts with both the SLBP/SL complex (Dominski et al. 2002) as well as the U7 snRNP specific Sm-like protein Lsm11 (Azzouz et al. 2005; Wagner et al. 2006) and is limiting for histone pre-RNA processing in vivo (Wagner and Marzluff 2006). Mutations in the stem–loop that abolish binding of SLBP result in no expression of processed histone mRNA in vivo (Pandey et al. 1994). The requirement of SLBP for in vitro processing of histone pre-mRNA in nuclear extracts from mammalian cells on many substrates is not absolute. Extracts depleted of SLBP are incapable of processing the H1t histone pre-mRNA but are competent to process the H2A-614 histone pre-mRNA (Dominski et al. 1999). The difference between these two substrates is that U7 snRNP base pairs more extensively with the HDE of H2A-614 than with the H1t HDE. Once the U7 snRNP is bound to the HDE, a cleavage factor is recruited containing at least CPSF73 (Dominski et al. 2005) and Symplekin (Kolev and Steitz 2005). CPSF73 is likely the endonuclease that cleaves the histone pre-mRNA from the DNA template (Dominski et al. 2005). The other components of the cleavage factor and the mechanism of recruitment of the cleavage factor to the U7 snRNP/SLBP/SL complex have not been elucidated. The molecular events that take place following processing in the nucleus and prior to the translation of histone mRNA in the cytoplasm are less well understood. What is clear is that the histone mRNA is rapidly exported (within 5 min) (Schochetman and Perry 1972), and export in Drosophila S2 cells (Erkmann et al. 2005a) and Xenopus oocytes (Huang and Steitz 2001) is dependent on TAP. SLBP is present in the cytoplasm only when histone mRNA is present (Erkmann et al. 2005b), where it is specifically associated with the histone mRNP (Whitfield et al. 2004; Townley-Tilson et al. 2006). In Xenopus oocytes, expression of SLBP stimulates the translation of reporter genes ending in a stem–loop (Sanchez and Marzluff 2002). Recently it has been reported that SLBP interacts with a novel protein, SLIP1, which also interacts with EIF4G and plays a role in translation of histone mRNA (Cakmakci et al. 2008). These data are all consistent with a role of SLBP in the translation of histone mRNA. In late S phase or when DNA replication is inhibited, histone mRNAs are rapidly degraded. The rapid decay of existing histone mRNA likely requires SLBP. Upf1 binds to SLBP at the 3′ end of histone mRNA immediately after inhibition of DNA replication and is required for histone mRNA degradation (Kaygun and Marzluff 2005a). Recently, we reported that an oligo(U) tail is added to the 3′ end of histone mRNA shortly after inhibiting DNA replication (Mullen and Marzluff 2008). This oligo(U) tail provides a binding site for Lsm1-7, which binds to the oligouridylated histone mRNA together with SLBP. The Lsm1-7 complex likely recruits the enzymes that degrade histone mRNA as it does for poly(A) mRNAs (Parker and Song 2004). SLBP is a cell-cycle regulated protein that accumulates just before entry into S-phase to activate histone pre-mRNA processing, and SLBP is degraded at the end of S-phase. Stabilization of SLBP by mutating the phosphorylation sites required for degradation does not affect degradation of histone mRNA (Zheng et al. 2003), indicating that SLBP degradation is not required for histone mRNA degradation. In order to understand the critical roles of SLBP in cells, we knocked down SLBP using RNA interference in U2OS cells. Previously, we, and others, had shown that reduction of SLBP levels results in a reduction in the rate of cell growth and an accumulation of cells in S-phase (Zhao et al. 2004; Wagner et al. 2005). However, a thorough molecular analysis of the effect of SLBP knockdown on histone mRNA metabolism has not been reported. Here we show that the major lesion in histone mRNA metabolism as a result of knocking down SLBP is not in histone pre-mRNA processing, but in the export of histone mRNA to the cytoplasm. Properly processed histone mRNA accumulates in the nucleus. Together, these results implicate SLBP as having a critical histone mRNA export function in mammalian cells, as well as its known roles in histone pre-mRNA processing, histone mRNA translation, and regulation of histone mRNA half-life. RESULTS SLBP is required for cell growth We determined the effect of knocking down SLBP in U2OS cells using a double-stranded siRNA that specifically targets SLBP mRNA. Previously we have shown that knockdown of SLBP with this siRNA results in an increase in S-phase cells, and that we can rescue this phenotype by expressing an RNAi-resistant SLBP. Moreover, Muller and colleagues (Zhao et al. 2004) demonstrated that reduced expression of SLBP also resulted in a defect in S-phase progression and a reduced expression of histone mRNAs. Both studies demonstrated S-phase defects but did not elucidate the specific molecular defects underlying this phenotype. Since we initially observed variable results, which were dependent on the extent of SLBP knockdown, we optimized the knockdown, both for extent and duration, allowing us to assay for histone mRNA metabolic defects while still maintaining efficient SLBP knockdown. We used Western blotting to monitor SLBP protein levels over various times throughout the RNAi transfection (Fig. 1A
As previously shown, knockdown of SLBP to this level resulted in an increase in the number of cells in S-phase (Wagner et al. 2005). We determined the rate of growth of the cells by measuring cell number at the various time points in Fig. 1A Reducing the levels of SLBP decreases the rate of DNA synthesis and activates an S-phase cell cycle checkpoint To confirm that the SLBP knockdown cells were accumulating in S-phase, we analyzed these cells by flow cytometry. We also asked whether these cells were still synthesizing DNA by pulsing the C2 or S2 siRNA treated U2OS cells with bromodeoxyuridine (BrdU), a thymidine analog, for 30 min followed by analysis of incorporation by FACS, using a FITC coupled anti-BrdU antibody. As a control, we treated cells transfected with C2 (control) siRNA with 5 mM hydroxyurea (HU) for 1 h to abolish BrdU incorporation. The DNA content was measured by propidium iodide staining, and the incorporation of BrdU was measured by FACS. As demonstrated previously, the SLBP knockdown cells accumulated in S-phase of the cell cycle (Fig. 1B We also used the BrdU FACS analysis to quantify the cell cycle phase distribution at a higher resolution in the SLBP knockdown cells compared to the C2 control (Fig. 1C We also determined the mitotic rate in the SLBP knockdown cells using an antibody to phosphorylated histone H3 (serine 10) as a mitotic marker. Positive cells were measured by FACS and were quantified as a percentage of the control (Fig. 1D We next determined whether the reduced rate of DNA replication resulted in activation of the S-phase checkpoint, a consequence of defective chromosome replication, damaged DNA, or environmental stress (Sancar et al. 2004). It has been shown previously that overexpression of a dominant-negative chromatin assembly factor 1 (CAF1) or RNAi to CAF1 produces a similar DNA replication phenotype as knocking down SLBP (Hoek and Stillman 2003; Ye et al. 2003). We hypothesized that reducing the levels of SLBP might result in impaired histone protein biosynthesis and hence mimic the defective chromatin assembly phenotype since the chromatin assembly machinery would not have enough histone proteins to properly assemble chromatin. We assessed the phosphorylation of Chk1, a kinase that is activated by the ATR kinase when DNA replication stress is sensed in S-phase cells. As a control, we again used C2 control cells treated with HU for 1 h since HU treatment is known to activate the DNA replication checkpoint (Sancar et al. 2004). There was increased Chk1 phosphorylation on both serine 345 (S345) and serine 317 (S317) in response to SLBP knockdown (Fig. 1E Processed histone mRNA levels are only reduced 50% in SLBP knockdown cells Since SLBP is involved in histone pre-mRNA processing, we determined the levels of histone mRNA, both by Northern blotting and by S1 nuclease mapping to assess whether the 3′-end was formed properly. We used Northern blots to determine histone mRNA levels for all five histone proteins, and each band represents mRNAs from five to 15 genes since the nucleotide sequences of the ORFs are very conserved (Marzluff et al. 2002). We used radiolabeled probes generated by PCR targeting the open reading frame (ORF) to detect histones H2A, H2B, H3, H4, and H1 and used 7SK snRNA as a loading control (Fig. 2A
We observed a slower migrating band in the histone H4 Northern blot (Fig. 2A Histone protein levels are reduced in SLBP knockdown cells Since there was still a substantial amount of properly processed histone mRNA in the SLBP knockdown cells for all the core histone proteins, we suspected that there must be a defect in histone protein production other than in histone pre-mRNA processing. Previous structure–function studies on SLBP have shown that there is a critical domain necessary for histone mRNA translation (Sanchez and Marzluff 2002; Gorgoni et al. 2005). Due to the modest decrease in properly processed histone mRNA in SLBP knockdown cells, we hypothesized that reduction of SLBP might have had a more dramatic effect on histone protein synthesis than on histone pre-mRNA processing. We therefore investigated the levels of histone protein in SLBP knockdown cells. Figure 3A
To directly test the effect of knockdown of SLBP on the amount of histone protein, nuclear proteins were prepared from nuclei of control cells and cells with SLBP knocked down. The Coomassie stained gel (Fig. 3B Regulation of histone mRNA degradation is impaired in SLBP knockdown cells Histone mRNA half-life is coordinately regulated with the rate of DNA synthesis, and at the completion of S phase or upon inhibition of DNA synthesis, there is a rapid degradation of histone mRNA. Histone mRNA degradation is a regulated process that requires translation of the histone mRNA (Graves et al. 1987; Kaygun and Marzluff 2005b), and involves the addition of an oligo(U) tail to the 3′end in order to recruit specific decay factors for rapid, bidirectional decay of the mRNA (Mullen and Marzluff 2008). Since reducing SLBP protein levels produced defects in DNA synthesis and normal histone gene expression, we asked if down-regulation of SLBP had an effect on histone mRNA degradation in HeLa cells. We inhibited DNA replication with 5 mM HU in both C2 control cells and SLBP knockdown cells for 30 and 60 min. The representative Northern blot analysis of histone H2A mRNA presented in Figure 3C Processed histone mRNA is retained in the nucleus in SLBP knockdown cells Another possibility for the low rate of histone protein synthesis is that the histone mRNA may be mislocalized. We determined the subcellular localization of the histone mRNA in SLBP knockdown cells. As a control experiment to localize histone mRNA, we synchronized HeLa cells using double thymidine block and released them into S phase for 3 h and performed in situ hybridization with a probe to histone H2A. Histone H2A mRNA is localized strongly around the nucleus in a halo-like appearance, although some signal is present throughout the cytoplasm (Fig. 4A
We performed in situ hybridization to histone H2A mRNA in HeLa and H3 mRNA in U2OS cells in which SLBP has been knocked down. In the control HeLa cells, histone H2A mRNA was present in the cytoplasm, with the halo-like appearance in the perinuclear region with little to no staining in the nucleus (Fig. 4B As an alternative approach to confirm the presence of histone mRNA in the nucleus, we fractionated C2 control and S2 knockdown cells into nuclear and cytoplasmic fractions. We harvested protein and total RNA from these fractions as well as from a portion of the total cell lysate. Hsp90 and fibrillarin were used as cytoplasmic and nuclear markers, respectively, and they were present almost exclusively in the appropriate fraction (Fig. 4D We also analyzed the histone mRNA in each of the subcellular fractions from the same experiment, and simultaneously probed for histone H3 mRNA and U1 snRNA as a control (Fig. 4F Taken together these results demonstrate that the major lesion in histone mRNA metabolism when SLBP is knocked down more than 95% is in export of the histone mRNA to the cytoplasm. Processed histone mRNA accumulates in the nucleus, and is relatively stable. Thus the primary molecular defect in histone mRNA metabolism when SLBP is knocked down to 2%–5% of normal levels is the retention of processed histone mRNA in the nucleus. Tethering of SLBP to nonspecific mRNA results in nuclear export Many general mRNA export factors, including TAP and Rev, promote export to the cytoplasm when tethered to nonspecific mRNAs (Yi et al. 2002). To determine if SLBP facilitates nuclear export of mRNA, we utilized a well-characterized CAT (chloramphenicol acetyl transferase) reporter system. The pDM128/PL reporter contains a CMV-driven bacterial CAT gene located within an intron derived from HIV-1. Under standard conditions, the CAT mRNA is spliced out of the reporter and not expressed due to its nuclear retention. Robust CAT activity can be achieved by the insertion of four MS2 binding sites adjacent to the CAT gene coupled with the expression of a heterologous fusion protein containing the MS2 coat protein and a factor capable of mRNA export (i.e., TAP). The activity results from the export of the CAT mRNA prior to it getting spliced out of the reporter. 293T cells were cotransfected with either pDM128/PL or pDM128/PL-4XMS2 and HA-MS2 fused to TAP, Rev, or SLBP. Expression of MS2-TAP and MS2-Rev resulted in increased levels of CAT activity from the pDM128/PL-4XMS2 reporter compared to the reporter lacking MS2 sites (Fig. 5A
DISCUSSION As the only mRNAs that are not polyadenylated, metazoan histone mRNAs require a distinct set of factors for pre-mRNA processing, translation, and regulation of stability. A common factor in all these processes is SLBP, which binds the stem–loop in the histone pre-mRNA during transcription, remains associated with the mRNA during translation, and is involved in histone mRNA degradation (Marzluff et al. 2008). Here we have ascertained the effect of knocking down SLBP in mammalian cells to <5% of the normal level. The cells remain viable and continue growing at a slow rate. Surprisingly, there is only a modest effect on the accumulation of processed histone mRNA, but a substantial fraction of the histone mRNA is retained in the nucleus, suggesting a previously unrecognized role of SLBP in histone mRNA export in vivo. We, and others, have previously shown that knocking down SLBP results in slow growth of cells and an accumulation of cells in S-phase (Zhao et al. 2004; Wagner et al. 2005). This effect is due to the SLBP knockdown since normal growth can be restored by expression of an RNAi-resistant SLBP (Wagner et al. 2005). Progression through S-phase was slowed as judged by the release of cells from either nocodazole or HU blocks (Zhao et al. 2004). This is in contrast to knocking down components of the U7 snRNP, which result in an arrest of cells in mid-G1 (Wagner and Marzluff 2006). This evidence suggests that the cell monitors the ability to synthesize histone mRNA by monitoring the presence of an active U7 snRNP, but that cells enter S phase normally when SLBP is reduced. SLBP is a relatively unstable protein, being degraded at the end of S-phase and not accumulating again until just prior to entry into the next S-phase (Whitfield et al. 2000; Zheng et al. 2003). Thus, it is relatively easy to obtain effective knockdown of the SLBP protein, although for the phenotypes observed here SLBP must be knocked down >95%, and with long exposures of the Western blots, we detect small amounts of SLBP in the knockdown cells. Thus, the results reported here reflect the phenotypes observed when SLBP is severely limiting but not absent from cells. The most obvious effect of knocking down SLBP is a slow growth rate and a change in cell cycle distribution of the cells, with an accumulation of cells in S-phase. The cells continue dividing, and we see no evidence of apoptosis during the five to six day course of the experiments. The accumulation of cells in S-phase is due to a slower progression through S phase as a result of a reduced rate of DNA replication (Fig. 1 Surprisingly, the overall level of histone mRNAs is only reduced about twofold in SLBP knockdown cells, and the great majority of the histone mRNA is accurately processed. This implies that the residual SLBP in the cell must be preferentially used for histone pre-mRNA processing. One possibility is that the residual SLBP might be concentrated in the Cajal body, where it could function in histone pre-mRNA processing, but we were not able to detect a specific localization by immunofluorescence. There is a small amount of misprocessed polyadenylated mRNA that accumulates from some of the histone genes, suggesting that the efficiency of processing is reduced in the SLBP knockdown mutants. The HIST2H2AA gene has been previously shown to have a cryptic polyadenylation site in the HDE that is used when histone processing is disrupted by insertion of an intron (Pandey et al. 1994), and in round spermatids (Moss et al. 1994). This mRNA is also polyadenylated when NELF, a transcription elongation inhibitor, is knocked down (Narita et al. 2007). There is also a polyadenylated histone H4 mRNA that accumulates when SLBP is knocked down. This mRNA is derived from a single histone H4 gene, HIST1H4J, which contains a polyadenylation signal in the 3′-UTR, just before the stem–loop. Although the position of the poly(A) tail is at the same site as the cleavage site for histone mRNA, it is likely that this polyadenylation signal, which overlaps the SLBP binding site, directs the cleavage of the HIST1H4J pre-mRNA to yield the polyadenylated mRNA. Each of these polyadenylation signals overlaps a cis-element required for histone mRNA processing, suggesting that normally the histone processing machinery preferentially associates with these signals. Unlike the situation in Drosophila (Lanzotti et al. 2002; Godfrey et al. 2006), there is not extensive read-through of histone transcripts resulting in polyadenylated mRNAs in mammalian cells when SLBP is reduced. This may reflect a need in Drosophila for efficient termination between closely spaced histone genes, or there may in fact be a role for polyadenylated histone mRNAs in particular cell types during development. The role of SLBP in the processing of histone pre-mRNA is “catalytic,” allowing cells to perform this function even under limiting concentration of SLBP, and then SLBP can be released for processing more histone mRNAs. However the requirement for SLBP in other steps in histone mRNA metabolism (e.g., export or translation) is likely stoichiometric, and the RNAi-mediated reduction in SLBP levels therefore interferes with these functions. Transport of histone mRNA Most mRNAs are transported through a pathway that requires TAP (yeast mex67p) as an adaptor protein for export (Erkmann and Kutay 2004). TAP can be recruited to mRNAs derived from spliced pre-mRNAs by binding to components of the exon–junction complex deposited near the exon–exon border after splicing. Unspliced mRNAs such as histone mRNAs must recruit TAP by a different mechanism. There have been several studies relevant to histone mRNA export from the nucleus. In one study the role of processing was assessed by forming the histone 3′ end either by a normal processing reaction or by ribozyme cleavage (Eckner et al. 1991). They found that mature histone mRNAs were cytoplasmic regardless of the mechanism of 3′ end formation. However, if the histone ORF was replaced with the chloramphenicol acetyl transferase ORF, then the mRNA formed by the processing reaction was cytoplasmic, and the mRNA formed by the ribozyme was retained in the nucleus.
Huang and Steitz (2001) studied elements in the histone ORF that were capable of directing transport of an heterologous mRNA in Xenopus oocytes and identified a binding site for the SR protein 9G8 responsible for this activity. The binding site is contained within a region of the histone ORF capable of conferring cytoplasmic localization on other unspliced mRNAs (Huang and Carmichael 1997). These studies suggest a role for 9G8 protein in recruiting TAP and provide a partial explanation for the observed conservation in the nucleotide sequence level in histone ORFs at that site (Debry and Marzluff 1994; Friend et al. 2007). In a previous study of histone mRNA export in Xenopus oocytes, we found there was not a requirement for any specific nucleotide sequence, including the 3′ end of histone mRNA or SLBP, for histone mRNA export (Erkmann et al. 2005a) in Xenopus oocytes. This study suggested there are multiple potential binding sites for proteins that could recruit TAP and that in Xenopus oocytes there is a large supply of these proteins, which is in agreement with other studies that showed the length of the RNA was a major determinant of its transport efficiency in Xenopus oocytes (Masuyama et al. 2004). In mammalian cells with active RNA metabolism, there is likely to be competition among the mRNAs for the binding proteins and export factors, just as there is for factors involved in RNA processing. Thus it is not surprising to find there might be more stringent requirements for export in mammalian cells than in Xenopus oocytes. Our results suggest there is a critical role for SLBP in histone mRNA export in mammalian cells. Overall, these results are consistent with a model wherein multiple factors may need to bind to a RNA for efficient export. The processing reaction may facilitate recruitment of some of these factors (Eckner et al. 1991), and there are clearly sequence elements in the histone ORF that promote export (Huang and Carmichael 1997; Huang and Steitz 2001) of mRNAs. Our results suggests that association of SLBP is necessary to promote efficient transport of histone mRNA but not to stabilize the histone mRNA in the nucleus. When SLBP levels are greatly reduced, mature histone mRNAs accumulate in the nucleus. A striking aspect of this result is that these mRNAs accumulate to substantial levels. When mutations are introduced into the histone stem–loop that alter SLBP binding (Pandey et al. 1994) or the HDE is deleted preventing U7 snRNP binding (Chodchoy et al. 1991), or when the HDE is naturally suboptimal (Liu et al. 1989), then the unprocessed mRNAs do not accumulate, but rather, must be rapidly degraded. The same is true of improperly processed mRNAs from polyadenylated transcripts. In the SLBP knockdown cells, histone mRNAs are properly processed, and direct sequencing of the mRNAs after circular RT-PCR (Mullen and Marzluff 2008) did not reveal any alterations at the 3′-end of the mRNA (E.J. Wagner, unpubl.). Thus these mature mRNAs, which are not bound to SLBP, are still stable in the nucleus. They may be stable in the nucleus since they have gone through the normal processing pathway, despite the fact that they cannot be exported. A model for histone mRNA export in normal cells and for the nuclear retention of histone mRNA in SLBP knockdown cells is shown in Figure 6
Decreased levels of histone protein in SLBP knockdown cells The second feature of the SLBP knockdown cells is that they have a lower amount of histone protein, consistent with a defect in histone protein biosynthesis. Initially we found this surprising, since one might think that reducing histone protein:DNA ratios twofold might have a profound effect on cell physiology and viability. However, in at least one situation, infection of human T lymphocytes with HTLV1, there is an approximately twofold reduction in histone:DNA ratios and mediated by a reduction in core histone mRNA expression without affecting DNA replication (Bogenberger and Laybourn 2008). In yeast one can vary the histone:DNA ratio by changing the dosage of the histone genes (Gunjan and Verreault 2003) or in some mutants by chromatin modification (Xiao et al. 2007; B.D. Strahl, pers. comm.) without affecting viability. Conclusions SLBP is essential for the proper accumulation of histones for assembly of newly replicated DNA into chromatin. Our results suggest that a major consequence of SLBP depletion is the failure to export properly processed histone mRNA. This suggests that SLBP must be associated with histone mRNA for export and that SLBP may dissociate from histone mRNA after processing and additional nucleoplasmic SLBP may then reassociate with the histone mRNA prior to export. Understanding and identifying the components of the nuclear histone mRNP, as well as the cytoplasmic histone mRNP, will help elucidate the pathway between processing of the mRNA at the site of transcription and subsequent export and translation of the histone mRNA. MATERIALS AND METHODS RNA interference RNAi was performed using a two-hit method as previously described using Lipofectamine 2000 (Wagner and Garcia-Blanco 2002). Briefly, 110,000 U2OS or 95,000 HeLa cells were plated into 24-well plates, and the following day, siRNAs were transfected into cells. A day following the first hit of siRNA, cells were replated into six well dishes, allowed to grow an additional day, and then transfected with the second hit of siRNA. Cells were harvested 48–72 h following the second hit for analysis. The siRNA sequences of the C2 (control) and S2 (SLBP) have been previously described (Wagner et al. 2005). DNA synthesis and mitotic index measurements by FACS We quantified the percentage of bromodeoxyuridine (BrdU) labeled cells in S phase and phospho-histone H3 in mitosis as previously described (Doherty et al. 2003). As controls for these assays, cells were treated with 5 mM HU for 1 h prior to addition of the BrdU. To measure DNA synthesis in S phase, RNAi-treated cells were pulsed with a 1 mM stock solution of BrdU (10 μM final concentration) for 1 h. Acid-treated nuclei were resuspended with 100 μL of a solution containing α-BrdU antibody conjugated to FITC (Becton Dickinson) diluted 1:5 in IFA (10 mM HEPES at pH 7.4, 150 mM NaCl, 4% FBS, 0.1% NaN3) plus 0.5% Tween-20 and incubated in the dark for 2 h at room temperature. Following the incubation, 2 mL of IFA plus 0.5% Tween-20 was added, and nuclei were recovered by centrifugation. Nuclei were resuspended in 500 μL of the IFA plus 0.5% Tween solution containing 5 μg/mL RNase A and 50 μg/mL propidium iodide. Nuclei were incubated overnight at 4°C and analyzed on a Becton-Dickinson (Becton Dickinson) FACScan using Summit Software (Dako Cytomation). To measure the mitotic index using phospho-histone H3 as a marker, cells were fixed with 1% formaldehyde in PBS for 30 min. Fixed cells were pelleted at 1200 rpm for 5 min at 4°C and the supernatant removed. Cells were resuspended in 1.5 mL of PBS, and then 3 mL of cold 100% ethanol was added and cells were stored overnight at 4°C. The cells were resuspended in 100 μL of a solution containing 0.5 μg of phospho-histone H3 (serine 10) antibody (Upstate Biotechnology) and 5 μg/mL RNase A in IFA plus 0.5% Tween-20 for 2 h at room temperature. The cell pellet was resuspended in 100 μL of the IFA plus 0.5% Tween-20 solution containing an anti-rabbit secondary antibody conjugated to FITC (Santa Cruz Biotechnology) for 1 h at room temperature. The cells were resuspended in 500 μL of the IFA plus 0.5% Tween solution containing 5 μg/mL RNase A and 50 μg/mL propidium iodide and analyzed by FACS. Northern blot analysis and S1 nuclease protection assays Northern blot analysis to replication-dependent histone genes and 7SK snRNA was performed as described previously (Mullen and Marzluff 2008). Briefly, 2 μg of total RNA was resolved on 6% urea–polyacrylamide gels, transferred to Hybond N+ nitrocellulose (Amersham Biosciences), and probed in QuickHyb (Stratagene) overnight at 60°C. Probes were generated by random primed, α32P-dCTP labeling (PrimeIt II Kit; Stratagene) of PCR products generated to the complete ORF of cloned human histone genes and to 7SK RNA (Mullen and Marzluff 2008). S1 nuclease protection assays to map the 3′ ends of histone H2a (HIST2H2AA) and H3 (HIST2H3A/C) were performed as previously described (Kaygun and Marzluff 2005a). Probes for 3′-end labeling were generated by digestion of the HIST2H2AA gene with AscI and the HISTH3A/C gene with BssHI. The digested plasmid DNA was 3′-end labeled with α32P-dCTP and Klenow (New England BioLabs) and hybridized with total cell RNA. Protected fragments were resolved on 6% urea–polyacrylamide gels. Western blot analysis Protein lysates from RNAi-treated cells were prepared as previously described (Mullen and Marzluff 2008) and the concentrations quantified using Bradford reagent. The primary antibodies used in this study include rabbit anti-SLBP (Wang et al. 1996), mouse anti-symplekin (BD Biosciences), rabbit anti-fibrillarin (Abcam), rabbit anti-Hsp90 (Cell Signaling Technology), and rabbit anti-histone H3 (Abcam). Protein were resolved on 12% SDS–polyacrylamide gels and transferred to nitrocellulose before detection using appropriate primary and secondary antibodies. In situ hybridization In situ hybridizations were performed as described (Erkmann et al. 2005a). RNAi-treated cells were grown on coverslips and washed with PBS and fixed in 3.7% PFA in PBS for 10 min at room temperature. Cells were then washed again and permeabilized in 0.5% Triton X-100 in PBS. Pre-hybridization was performed for 10 min at 37°C using a solution of 4× SSC and 50% formamide preheated to 37°C. Coverslips were inverted onto a 5–10-μL drop of hybridization solution (50% deionized formamide, 10% dextran sulfate, 1× Denhardt's solution, 4× SSC, 1 mg/mL Escherichia coli tRNA) containing 1 ng/μL DIG labeled H2A or H3 probe. Probes were denatured for 5 min at 80°C and cooled on ice prior to addition to hybridization solution. Hybridizations were performed overnight at 37°C in a humidified chamber. Cells were washed once with 2× SSC at 37°C, 3× in 60% formamide in 0.2× SSC at 37°C, once in 2× SSC at room temperature, and 3× with 0.5% Tween-20 in 4× SSC. Coverslips were inverted onto 8-μL drops of 0.5% Tween-20 in 4× SSC containing mouse Cy3 α-DIG antibody diluted 1:200 and incubated for 1 h at 37°C in a humidified chamber. Coverslips were washed three times with 0.5% Tween-20 in 4× SSC and inverted onto 8-μL drops of 0.5% Tween-20 in 4× SSC containing Cy-3 α-mouse secondary antibody diluted 1:200. Secondary incubation was performed for 45 min at 37°C in a humidified chamber. Coverslips were washed 3× with 0.5% Tween-20 in 4× SSC before being fixed with 3.7% PFAin PBS for 5 min at room temperature. After a PBS wash, coverslips were DAPI-stained and mounted onto slides using Fluorsave reagent (Calbiochem). Images were acquired using a Zeiss LSM 510 confocal microscope and analyzed using ImageJ software. CAT assay CAT assays were performed essentially as described (Cullen 2004). 293T cells (3 × 105) were cotransfected with 25 ng of reporter plasmid and 500 ng of MS2-fusion plasmid using Lipofectamine-2000. Forty-eight hours after transfection, cells were harvested in TEN buffer (100 mM NaCl, 10 mM EDTA, 10 mM Tris-HCl at pH 7.5), pelleted, and resuspended in 100 μL of 100 mM Tris-HCl (pH7.5). Cells were lysed by freeze–thawing three times, and lysates were pelleted for 5 min at 4°C. Equal amounts of lysates were added to 300 μL of CAT assay buffer (5 mg/mL chlorampenicol in 100 mM Tris-HCl at pH 7.5 containing 1 μL/mL [3H]acetyl coenzyme A). Three milliliters of Econofluor (Packard) scintillation cocktail was added to each sample, and counts were determined in a scintillation counter. ACKNOWLEDGMENTS We thank the members of the Marzluff laboratory for critical discussions during the preparation of this manuscript and Hal Boegerd and Heater Karnowski from Brian Cullen's laboratory (Duke University) for advice on the transport assays. This research was supported by NIH grant GM29832 to W.F.M. K.D.S. was supported from NIH training grant T32GM008581, and E.J.W. is funded by NIH fellowship F32GM070101 and Pathway to Independence Award K99GM080447. Footnotes Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.1205409. REFERENCES
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Curr Opin Cell Biol. 2005 Jun; 17(3):274-80.
[Curr Opin Cell Biol. 2005]Science. 1987 Dec 18; 238(4834):1682-7.
[Science. 1987]Mol Cell Biol. 1999 May; 19(5):3561-70.
[Mol Cell Biol. 1999]Mol Cell Biol. 2001 Mar; 21(6):2008-17.
[Mol Cell Biol. 2001]Genes Dev. 2002 Jan 1; 16(1):58-71.
[Genes Dev. 2002]Mol Cell Biol. 1999 May; 19(5):3561-70.
[Mol Cell Biol. 1999]Cell. 2005 Oct 7; 123(1):37-48.
[Cell. 2005]Genes Dev. 2005 Nov 1; 19(21):2583-92.
[Genes Dev. 2005]J Mol Biol. 1972 Feb 14; 63(3):591-6.
[J Mol Biol. 1972]Mol Cell. 2001 Apr; 7(4):899-905.
[Mol Cell. 2001]Nucleic Acids Res. 2004; 32(16):4833-42.
[Nucleic Acids Res. 2004]RNA. 2006 Oct; 12(10):1853-67.
[RNA. 2006]Mol Cell Biol. 2002 Oct; 22(20):7093-104.
[Mol Cell Biol. 2002]Genes Dev. 2008 Jan 1; 22(1):50-65.
[Genes Dev. 2008]Nat Struct Mol Biol. 2004 Feb; 11(2):121-7.
[Nat Struct Mol Biol. 2004]Mol Cell Biol. 2003 Mar; 23(5):1590-601.
[Mol Cell Biol. 2003]J Cell Sci. 2004 Dec 1; 117(Pt 25):6043-51.
[J Cell Sci. 2004]Biochem Soc Trans. 2005 Jun; 33(Pt 3):471-3.
[Biochem Soc Trans. 2005]J Cell Sci. 2004 Dec 1; 117(Pt 25):6043-51.
[J Cell Sci. 2004]Biochem Soc Trans. 2005 Jun; 33(Pt 3):471-3.
[Biochem Soc Trans. 2005]Proc Natl Acad Sci U S A. 2003 Oct 14; 100(21):12183-8.
[Proc Natl Acad Sci U S A. 2003]Annu Rev Biochem. 2004; 73():39-85.
[Annu Rev Biochem. 2004]Proc Natl Acad Sci U S A. 2003 Oct 14; 100(21):12183-8.
[Proc Natl Acad Sci U S A. 2003]Mol Cell. 2003 Feb; 11(2):341-51.
[Mol Cell. 2003]Annu Rev Biochem. 2004; 73():39-85.
[Annu Rev Biochem. 2004]Genomics. 2002 Nov; 80(5):487-98.
[Genomics. 2002]J Cell Sci. 2004 Dec 1; 117(Pt 25):6043-51.
[J Cell Sci. 2004]Nucleic Acids Res. 1990 Jun 11; 18(11):3161-70.
[Nucleic Acids Res. 1990]Genetics. 1994 Sep; 138(1):191-202.
[Genetics. 1994]Nucleic Acids Res. 1994 Aug 11; 22(15):3160-6.
[Nucleic Acids Res. 1994]Mol Cell. 2007 May 11; 26(3):349-65.
[Mol Cell. 2007]Mol Cell Biol. 2002 Oct; 22(20):7093-104.
[Mol Cell Biol. 2002]RNA. 2005 Jul; 11(7):1030-42.
[RNA. 2005]Mol Cell Biol. 2000 Mar; 20(5):1515-25.
[Mol Cell Biol. 2000]Cell. 1987 Feb 27; 48(4):615-26.
[Cell. 1987]Genes Dev. 2008 Jan 1; 22(1):50-65.
[Genes Dev. 2008]Biochem Soc Trans. 2005 Jun; 33(Pt 3):471-3.
[Biochem Soc Trans. 2005]RNA. 2002 Feb; 8(2):180-7.
[RNA. 2002]Mol Cell. 2001 Aug; 8(2):397-406.
[Mol Cell. 2001]Mol Cell Biol. 2002 Jan; 22(1):245-56.
[Mol Cell Biol. 2002]Nat Rev Genet. 2008 Nov; 9(11):843-54.
[Nat Rev Genet. 2008]J Cell Sci. 2004 Dec 1; 117(Pt 25):6043-51.
[J Cell Sci. 2004]Biochem Soc Trans. 2005 Jun; 33(Pt 3):471-3.
[Biochem Soc Trans. 2005]Mol Cell Biol. 2006 Sep; 26(17):6702-12.
[Mol Cell Biol. 2006]Mol Cell Biol. 2000 Jun; 20(12):4188-98.
[Mol Cell Biol. 2000]Mol Cell Biol. 2003 Mar; 23(5):1590-601.
[Mol Cell Biol. 2003]Mol Cell. 2003 Feb; 11(2):341-51.
[Mol Cell. 2003]Mol Cell Biol. 1994 Mar; 14(3):1709-20.
[Mol Cell Biol. 1994]Nucleic Acids Res. 1994 Aug 11; 22(15):3160-6.
[Nucleic Acids Res. 1994]Mol Cell. 2007 May 11; 26(3):349-65.
[Mol Cell. 2007]Mol Cell Biol. 2002 Apr; 22(7):2267-82.
[Mol Cell Biol. 2002]RNA. 2006 Mar; 12(3):396-409.
[RNA. 2006]Exp Cell Res. 2004 May 15; 296(1):12-20.
[Exp Cell Res. 2004]EMBO J. 1991 Nov; 10(11):3513-22.
[EMBO J. 1991]Mol Cell. 2001 Apr; 7(4):899-905.
[Mol Cell. 2001]Proc Natl Acad Sci U S A. 1997 Sep 16; 94(19):10104-9.
[Proc Natl Acad Sci U S A. 1997]Genetics. 1994 Sep; 138(1):191-202.
[Genetics. 1994]Mol Cell. 2007 Oct 26; 28(2):240-52.
[Mol Cell. 2007]Genes Dev. 2004 Sep 1; 18(17):2074-85.
[Genes Dev. 2004]EMBO J. 1991 Nov; 10(11):3513-22.
[EMBO J. 1991]Proc Natl Acad Sci U S A. 1997 Sep 16; 94(19):10104-9.
[Proc Natl Acad Sci U S A. 1997]Mol Cell. 2001 Apr; 7(4):899-905.
[Mol Cell. 2001]Mol Cell Biol. 1994 Mar; 14(3):1709-20.
[Mol Cell Biol. 1994]Mol Cell Biol. 1991 Jan; 11(1):497-509.
[Mol Cell Biol. 1991]Mol Cell Biol. 1989 Aug; 9(8):3499-508.
[Mol Cell Biol. 1989]Genes Dev. 2008 Jan 1; 22(1):50-65.
[Genes Dev. 2008]Retrovirology. 2008 Jan 31; 5():9.
[Retrovirology. 2008]Cell. 2003 Nov 26; 115(5):537-49.
[Cell. 2003]Mol Cell Biol. 2007 Jan; 27(2):721-31.
[Mol Cell Biol. 2007]Mol Cell. 2002 Oct; 10(4):943-9.
[Mol Cell. 2002]Biochem Soc Trans. 2005 Jun; 33(Pt 3):471-3.
[Biochem Soc Trans. 2005]J Natl Cancer Inst. 2003 Dec 17; 95(24):1859-68.
[J Natl Cancer Inst. 2003]Genes Dev. 2008 Jan 1; 22(1):50-65.
[Genes Dev. 2008]Genes Dev. 2008 Jan 1; 22(1):50-65.
[Genes Dev. 2008]Genes Dev. 1996 Dec 1; 10(23):3028-40.
[Genes Dev. 1996]Methods Mol Biol. 2004; 257():85-92.
[Methods Mol Biol. 2004]